New drug combo aims to stop breast cancer from coming back

NCT ID NCT03285412

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This Phase 2 trial is testing whether adding the drug ribociclib (Kisqali) to standard hormone therapy can improve outcomes for people with early-stage ER-positive breast cancer. The study involves 120 participants and focuses on clearing cancer DNA from the blood. The goal is to find a more effective way to prevent the cancer from returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ribociclib (Kisqali) plus endocrine therapy
What this could lead to: If successful, this could lead to a more effective treatment plan for early-stage ER+ breast cancer, potentially reducing the risk of recurrence.
What could go wrong: This is a Phase 2 trial with only 120 participants, so results may not apply to everyone. Side effects from ribociclib can include fatigue, nausea, and low blood cell counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Mass General/North Shore Cancer Center

Danvers, Massachusetts, 01923, United States
Massachusetts General Hospital

Boston, Massachusetts, 02214, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.